Case reports of first experiences worldwide with novel continuous oral levodopa dental pump in Parkinson’s Disease Patients
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of a novel continuous levodopa-carbidopa oral pump (LCOP) delivery system in patients with early PD. Background:…Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
Objective: To determine the relative bioavailability of levodopa when administered as a subcutaneous (SC) levodopa/carbidopa (LD/CD) infusion with ND0612 versus levodopa derived from oral immediate-release…Women with Parkinson’s Disease (PD) and High Coffee Use Have a Shorter Time to Medication Initiation
Objective: Investigate how coffee use prior to PD diagnosis affects medication initiation in PD. Background: Population studies show a decreased incidence of PD for men…PD+: A comprehensive, user-friendly mobile application for clinicians treating Parkinson’s Disease
Objective: We developed a mobile application that converts dopaminergic medication dosages and calculates total Levodopa (L-dopa) equivalent daily dose (LEDD) in a Parkinson’s Disease (PD)…Delayed Osmotic Demyelination Syndrome- An Evolving Spectrum
Objective: To report a case of osmotic demyelination syndrome (ODS) with continuing clinical and radiological worsening beyond its previously established temporal course. Background: ODS is…Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg on the pharmacokinetics (PK) of levodopa (LD) in different LD/carbidopa (LD/CD)…Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612
Objective: To describe the long-term experience of three individual patients receiving subcutaneous (SC) levodopa/carbidopa infusion with ND0612 in an open-label clinical safety study. Background: ND0612…Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status
Objective: To identify which gait metrics better distinguish PD-OFF from PD Best-ON and PD from HC, using a dimensionality-reduction method Background: Objective gait analysis using…Clinical Characteristics of patients with Parkinson’s disease showing normal values on SBR in the DAT SPECT
Objective: The aim of this study was to clarify what the ‘normal’ values of the specific binding ratio (SBR), a measure of striatal radiotracer uptake…Quality of life and patient reported outcomes with subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 BeyoND study
Objective: To review quality of life and other patient reported outcomes data from the ND0612 BeyoND study. Background: ND0612 is in development as a continuous,…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 70
- Next Page »